6.5
Impella
®
System for Use During Cardiogenic Shock
Figure 6.2 Lactate levels seen post-implant during the trial
The effectiveness endpoint, which was the primary endpoint of the study, was the change of
cardiac index from baseline after device support. The ISAR-SHOCK study showed a significant
improvement of cardiac index in the Impella 2.5 arm compared to the IABP arm post device
insertion, as shown in Figure 6.3. In addition, after 24 hours of support, fewer patients
supported with the Impella 2.5 required inotropes compared to patients supported with an IABP,
as shown in Figure 6.4.
Figure 6.3 Increase in cardiac index from baseline, Impella vs. IABP 30 minutes post-
support, in patients treated for cardiogenic shock after an AMI (ISAR-SHOCK)
6
C
LIN
IC
A
L E
X
P
E
RI
E
N
C
E
Summary of Contents for Impella 2.5
Page 4: ......
Page 8: ......
Page 10: ......
Page 12: ......
Page 15: ...2 WARNINGS AND CAUTIONS WARNINGS 2 1 CAUTIONS 2 3...
Page 16: ......
Page 22: ......
Page 38: ......
Page 40: ......
Page 108: ......
Page 171: ......
Page 173: ......
Page 181: ......
Page 183: ......
Page 201: ......
Page 203: ......
Page 205: ......
Page 210: ...INDEX TBD...